Committed to fostering collaborative and productive commercial partnerships
With a track record of successful product- and technology-based collaborations with top-tier pharmaceutical and biotechnology companies, we are a proven industry partner focused on leveraging our capabilities to form long-lasting and productive relationships.
We are highly motivated to build strategic alliances that will help to improve patients’ lives by creating and developing innovative and differentiated antibody-based therapeutics.
Building partnerships that drive innovation
Genmab’s ability to build upon knowledge of disease targets to create antibody therapeutics has attracted numerous partners. To maximize the value of our human antibody engineering and development capabilities and our proprietary technology platforms, Genmab forms collaborations with other biotechnology and pharmaceutical companies to create or co-develop antibody products for novel disease targets.
Our current partners
In June 2020, Genmab and AbbVie entered into a broad collaboration to jointly develop and commercialize Genmab’s next-generation bispecific antibody products epcoritamab, DuoHexaBody®-CD37 and DuoBody®-CD3x5T4. The companies also entered into a discovery research collaboration to select and develop up to four additional differentiated next-generation antibody-based product candidates. For epcoritamab Genmab will book net sales in the U.S. and Japan and receive tiered royalties on remaining global sales. For DuoHexaBody-CD37, DuoBody-CD3x5T4 and any product candidates developed as a result of the companies’ discovery research collaboration, Genmab and AbbVie will share responsibilities for global development and commercialization in the U.S. and Japan.
In June 2013, Genmab entered an agreement to develop a new antibody-drug conjugate (ADC) camidanlumab tesirine, combining Genmab’s HuMax®-TAC antibody with ADC Therapeutics’ PBD-based warhead and linker technology. In October 2020, an amended agreement was announced for ADC therapeutics to continue the development and commercialization of camidanlumab tesirine and Genmab to receive mid-to-high single-digit tiered royalty on net sales.
Genmab has a direct license for exclusive worldwide rights to Amgen’s patent estate relating to antibodies to IL15 and the IL15 receptor. In July 2003, Amgen exercised its commercialization options for the HuMax®-IL15 antibody program (now AMG 714). Amgen has partnered with Provention Bio to conduct and fund a Phase 2b trial with AMG 714 in non-responsive celiac disease (NRCD).
In May 2015, Genmab entered an agreement with BioNTech to jointly, on a 50:50 basis, research, develop and commercialize bispecific antibody products applying Genmab’s proprietary DuoBody® technology in combination with our joint target identification and product concept expertise. In 2019, DuoBody®-PD-L1x4-1BB and DuoBody®-CD40x4-1BB were the first product candidates from this partnership to enter clinical development.
In July 2019, Genmab and BliNK Biomedical entered into an exclusive commercial license to certain antibodies targeting CD47, for potential development and commercialization into novel bispecific therapeutics created via Genmab’s proprietary DuoBody® technology platform.
Bolt Biotherapeutics, Inc.
In June 2021, Genmab and Bolt entered into an oncology research and development collaboration. Together, the companies will evaluate Genmab antibodies and bispecific antibody engineering technologies in combination with Bolt’s proprietary immune-stimulating antibody conjugate (ISAC) technology platform, with the goal of discovering and developing next-generation, immune-stimulatory, antibody-based conjugate therapeutics. This research collaboration will evaluate multiple bispecific ISAC concepts to identify up to three clinical candidates for development. Genmab will fund the research, along with the preclinical and clinical development of these candidates through clinical proof of concept.
Bristol Myers Squibb
In December 2019, Genmab and CureVac AG announced a strategic partnership that will focus on the research and development of differentiated mRNA-based antibody products by combining CureVac’s mRNA technology and know-how with Genmab’s proprietary antibody technologies and expertise.
H. Lundbeck A/S
Genmab and H. Lundbeck A/S entered an agreement to create and develop human antibody therapeutics for disorders of the central nervous system (CNS) in October 2010.
Immatics Biotechnologies GmbH
In July 2018, Genmab and Immatics Biotechnologies GmbH entered into a research collaboration and exclusive license agreement to discover and develop next-generation bispecific immunotherapies to target multiple cancer indications. The deal combines Genmab’s proprietary technologies and antibody know-how with Immatics’ XPRESIDENT® targets and T-cell receptor (TCR) capabilities. Genmab will receive an exclusive license to three proprietary targets from Immatics, with an option to license up to two additional targets at predetermined economics. The companies will conduct joint research, funded by Genmab, on multiple antibody and/or TCR-based bispecific therapeutic product concepts.
Janssen Biotech, Inc.
In July 2012, Genmab entered into a collaboration with Janssen Biotech, Inc., one of the Janssen Pharmaceutical Companies of Johnson & Johnson, to create and develop bispecific antibodies using our DuoBody® technology platform. Genmab created panels of bispecific antibodies to multiple disease target combinations identified by Janssen that they are developing further in both the research setting and in clinical trials.
Janssen Biotech, Inc.
In August 2012, Genmab announced a global license and development agreement for daratumumab with Janssen Biotech, Inc., one of the Janssen Pharmaceutical Companies of Johnson & Johnson. Under the terms of the agreement, Genmab granted Janssen an exclusive worldwide license to develop and commercialize daratumumab.
Janssen Biotech, Inc.
Building on the successful collaboration on daratumumab in July 2019, Genmab entered into an exclusive worldwide license and option agreement with Janssen Biotech, Inc. to develop and commercialize HexaBody®-CD38, a next-generation human CD38 monoclonal antibody product incorporating Genmab’s proprietary HexaBody® technology.
Novartis Pharma AG
Genmab and GlaxoSmithKline (GSK) entered a co-development and collaboration agreement for ofatumumab in 2006. The full rights to ofatumumab were subsequently transferred from GSK to Novartis in 2015. Novartis is now responsible for the development and commercialization of ofatumumab in all potential indications. Genmab is entitled to potential sales milestones, in addition to 10 percent royalty payment of net sales. Novartis is fully responsible for all costs associated with developing and commercializing ofatumumab.
In August 2015, Genmab entered an agreement to grant Novo Nordisk commercial licenses to use the DuoBody® technology platform to create and develop bispecific antibody candidates for two therapeutic programs outside of cancer therapeutics. In December 2017, the collaboration was expanded to include an additional five potential target pair combinations and three commercial license options.
In May 2001, Genmab entered a collaboration with Roche to develop human antibodies to disease targets identified by Roche. In 2002, this alliance was expanded, and Roche made an equity investment in Genmab. Under the agreement, Genmab will receive milestones as well as royalty payments on successful products and, in certain circumstances, Genmab could obtain rights to develop products based on disease targets identified by Roche.
In September 2010, Genmab and Seagen entered into an antibody-drug conjugate (ADC) research collaboration agreement. Under the agreement, Genmab has rights to utilize Seagen’s ADC technology with its HuMax®-TF antibody and Seagen has the right to exercise a co-development option for any resulting ADC products at the end of Phase 1 clinical development. In September 2014, Genmab entered into an additional ADC collaboration with Seagen to utilize Seagen’s ADC technology with Genmab’s HuMax®-AXL antibody. On November 24, 2020 Genmab announced that it would not advance the development of enapotamab vedotin.
In October 2011, Genmab and Seagen entered into a commercial license and collaboration agreement for antibody-drug conjugates (ADCs). Under the agreement, Genmab was granted rights to utilize Seagen’s ADC technology with its HuMax®-TF antibody. In 2017, Seagen exercised its option to co-develop tisotumab vedotin, and the companies share all future costs and profits for the product on a 50:50 basis. In 2020, both companies entered into a commercialization agreement to continue joint decision-making on the worldwide development and commercialization strategy for tisotumab vedotin.
In September 2019, Genmab entered into a collaboration agreement with Tempus, which built upon existing service agreements between the companies. Under the terms of the collaboration agreement, the companies will jointly work on research projects that are identified by Genmab to explore novel product concepts and biomarkers. For any resulting products, Genmab will lead all development and commercial activities. Tempus will be eligible for undisclosed milestones and royalties from Genmab and will also have the option to fund part of product development programs in exchange for increased royalty payments due to Tempus under the agreement.
Develop next-generation antibody therapeutics with us.
Turning insights into medicine
See the results of innovation that is rooted in science
Innovation for the future
We are developing next-generation technologies
Events & presentations
As leaders in the industry, we are proud to share our work